Elicio Therapeutics annual operating margin
2020
2021
2022
Elicio Therapeutics's operating margin was −1,031.42% for fiscal 2022.
View full Elicio Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −1,031.42% | −888.52 pp |
| 2021 | 2021-12-31 | −142.90% | +28495.96 pp |
| 2020 | 2020-12-31 | −28,638.86% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2022 | 2022-06-30 | −954.36% | +2424.15 pp |
| Q1 2022 | 2022-03-31 | −878.94% | +4495.45 pp |
| Q4 2021 | 2021-12-31 | 58.22% | +7234.39 pp |
| Q3 2021 | 2021-09-30 | −1,079.32% | — |
| Q2 2021 | 2021-06-30 | −3,378.52% | — |
| Q1 2021 | 2021-03-31 | −5,374.39% | — |
| Q4 2020 | 2020-12-31 | −7,176.17% | — |
Across the available reported history, Elicio Therapeutics's operating margin decreased from −142.90% to −1,031.42%, a change of −888.52 percentage points. The latest reported quarter, Q2 2022, shows −954.36%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elicio Therapeutics filings at SEC.gov ↗